<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04578756</url>
  </required_header>
  <id_info>
    <org_study_id>3070-301-001</org_study_id>
    <nct_id>NCT04578756</nct_id>
  </id_info>
  <brief_title>Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder</brief_title>
  <official_title>A 26-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine&#xD;
      in the treatment of pediatric participants with schizophrenia or bipolar I disorder, and to&#xD;
      establish the benefit-risk profile of long-term treatment in this population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 4, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs) in the Treatment Period</measure>
    <time_frame>Baseline Day 1 to Week 30</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A TEAE is an AE that occurs or worsens after receiving study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Newly Emergent Adverse Events (NEAEs) in the Safety Follow-up Period</measure>
    <time_frame>Baseline Day 1 to Week 30</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (i.e. laboratory value), symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product. A NEAE is a new AE that occurred during the Safety Follow-up Period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters</measure>
    <time_frame>Baseline Day 1 to Week 26</time_frame>
    <description>Clinical laboratory parameters included tests of hematology, chemistry, urinalysis and prolactin. The investigator assessed the results for clinical significance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters</measure>
    <time_frame>Baseline Day 1 to Week 30</time_frame>
    <description>Vital sign parameters included blood pressure, pulse rate, body mass index (BMI), weight, and waist circumference. The investigator assessed the results for clinical significance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes From Baseline in Electrocardiograms (ECG)</measure>
    <time_frame>Baseline Day 1 to Week 26</time_frame>
    <description>A standard 12-lead ECG was performed. The investigator determined the clinical significance of the ECG findings using the central ECG interpretation laboratory report.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Suicidal Ideation or Suicidal Behavior as Recorded on the Columbia-Suicide Severity Rating (C-SSRS) Scale</measure>
    <time_frame>Baseline Day 1 to Week 26</time_frame>
    <description>C-SSRS is a clinician-rated scale that reports the severity of both suicidal ideation and behavior. Suicidal ideation is classified on a 5-item scale: 1 &quot;wish to be dead,&quot; and 5 &quot;active suicidal ideation with specific plan and intent&quot;. Suicidal behavior is classified on a 5-item scale: 0 &quot;no suicidal behavior, and 4 &quot;actual attempt&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) Score (Participants With Schizohrenia Only)</measure>
    <time_frame>Baseline Day 1 to Week 26</time_frame>
    <description>The Calgary Depression Scale (CDSS) is a 9-item scale specifically developed for the assessment of depression in participants with schizophrenia. All items are rated on a 4-point scale: 0 = absent; 1 = mild; 2 = moderate; 3 = severe.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Children's Depression Rating Scale - Revised (CDRS-R) (Participants with Bipolar I Disorder Only)</measure>
    <time_frame>Baseline Day 1 to Week 26</time_frame>
    <description>CDRS-R is a 17-item, clinician-administered scale specifically developed for the assessment of depressive symptoms in pediatric participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>Baseline Day 1 to Week 26</time_frame>
    <description>AIMS assesses abnormal involuntary movements, such as tardive dyskinesia, associated with antipsychotic drugs; it measures facial, oral, extremities, and trunk movements, as well as the participant's awareness of abnormal movements. The first 10 items are rated on a none (0) to severe (4) scale. There are an additional 2 items on dental status that are answered yes or no.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Barnes Akathisia Rating Scale (BARS)</measure>
    <time_frame>Baseline Day 1 to Week 26</time_frame>
    <description>BARS is a 4-item rating scale used to assess drug-induced akathisia. The scale comprises items for rating the observable restless movements that characterize the condition, the subjective awareness of restlessness, and any distress associated with the akathisia (each on a 4-point scale from normal [0] to severe [3]). In addition, there is a global severity for akathisia rated on a 6-point scale (absent [0] to severe akathisia [5]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Simpson-Angus Scale (SAS)</measure>
    <time_frame>Baseline Day 1 to Week 26</time_frame>
    <description>SAS is a 10-item rating scale for assessment of antipsychotic-induced parkinsonism in both clinical practice and research settings. Each item ranges from 0 (normal) to 4 (extreme symptoms). The scale consists of 1 item measuring gait (hypokinesia), 6 items measuring rigidity, and 3 items measuring glabella tap, tremor, and salivation, respectively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Changes From Baseline in Opthalmologic Parameters</measure>
    <time_frame>Baseline Day 1 to Week 26</time_frame>
    <description>Ocular examination parameters included Intraocular pressure (IOP) measurement, Best-corrected visual acuity (BCVA), color fundus photography, color vision testing using Hardy Rand and Rittler (HRR) plates, and assessment of Optical coherence tomography (OCT) and cataracts. The investigator assessed the results for clinical significance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Menstrual Onset Shift (Female Participants Only)</measure>
    <time_frame>Baseline Day 1 to Week 26</time_frame>
    <description>Female participants who have entered menarche will be asked for the date of the first day of their most recent menstrual period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Participants Shifting in Tanner Staging</measure>
    <time_frame>Baseline Day 1 to Week 26</time_frame>
    <description>Tanner staging is a scale for assessing physical development in children, adolescents, and adults. The scale defines physical measurements of development based on external primary and secondary sex characteristics, such as the size of the breasts, genitalia, and development of pubic hair.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>Cariprazine Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Schizophrenia 13 to 17 years will receive cariprazine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cariprazine Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Bipolar I Disorder, 10 to 12 years (weighing &lt;=40 kg) will receive cariprazine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cariprazine Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Bipolar I Disorder, 10 to 12 years (weighing &gt;40 kg) will receive cariprazine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cariprazine Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Bipolar I Disorder, 13 to 17 years will receive cariprazine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cariprazine Flexible Dose</intervention_name>
    <description>1 capsule to be taken orally at approximately the same time of day (morning or evening)</description>
    <arm_group_label>Cariprazine Dose 1</arm_group_label>
    <arm_group_label>Cariprazine Dose 2</arm_group_label>
    <arm_group_label>Cariprazine Dose 3</arm_group_label>
    <arm_group_label>Cariprazine Dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition&#xD;
             (DSM-5) primary diagnosis of schizophrenia or bipolar I disorder as confirmed by&#xD;
             Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age&#xD;
             Children-Present and Lifetime Version (K-SADS-PL).&#xD;
&#xD;
          -  Participant must have normal physical examination findings, clinical laboratory test&#xD;
             results, and ECG results at Screening Visit 1, or from the last visit of respective&#xD;
             lead-in study, or abnormal results that are determined to be not clinically&#xD;
             significant by the investigator.&#xD;
&#xD;
          -  Negative serum beta-human chorionic gonadotropin (Î²-hCG) pregnancy test (all female&#xD;
             participants).&#xD;
&#xD;
          -  Participants (if reached his spermarche or her menarche) and is sexually active, must&#xD;
             agree to sexual abstinence or to use an approved birth control method for the full&#xD;
             duration of participation in the study. The investigator and each participant will&#xD;
             determine the appropriate method of contraception for the participant during their&#xD;
             participation in the study.&#xD;
&#xD;
          -  Parent(s) or participant's legal representative(s) must be capable of giving signed&#xD;
             Informed Consent, which includes compliance with the requirements and restrictions&#xD;
             listed in the ICF and in this protocol as explained by the investigator. Written&#xD;
             informed consent from the Parent(s) or participant's legal representative(s) must be&#xD;
             obtained prior to any study-related procedures.&#xD;
&#xD;
          -  Informed assent (unless local regulations require consent) must be obtained for all&#xD;
             participants before eligibility evaluation for enrollment in the study.&#xD;
&#xD;
               -  For 10-11-year-old participants, a different assent form will be used than that&#xD;
                  for 12-17-year-old participants.&#xD;
&#xD;
          -  Participant must have a caregiver (parent or legally authorized representative) who is&#xD;
             willing and able to be responsible for safety monitoring of the participant, provide&#xD;
             information about the participant's condition, oversee administration of study&#xD;
             intervention, and accompany the participant to all study visits.&#xD;
&#xD;
          -  Participant must be able to swallow the study intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with DSM-5 diagnosis of schizoaffective disorder, schizophreniform&#xD;
             disorder, brief psychotic disorder, or psychotic disorder due to another medical&#xD;
             condition.&#xD;
&#xD;
          -  DSM-5 diagnosis of intellectual disability (IQ &lt; 70).&#xD;
&#xD;
          -  Participant has a history of meeting DSM-5 diagnosis for any substance-related&#xD;
             disorder (except caffeine- and tobacco-related) within the 3 months before Screening&#xD;
             (Visit 1) of the respective lead-in study, and/or within the 3 months before Visit 1&#xD;
             of this open-label (OL) study.&#xD;
&#xD;
          -  Participant with an acute or unstable medical condition, including (but not limited&#xD;
             to) inadequately controlled diabetes, hepatic insufficiency (specifically any degree&#xD;
             of jaundice), uncorrected hyper- or hypo-thyroidism, acute systemic infection, renal,&#xD;
             gastrointestinal, respiratory, or cardiovascular disease.&#xD;
&#xD;
          -  Severe head trauma.&#xD;
&#xD;
          -  History of seizures, with the exception of febrile seizures.&#xD;
&#xD;
          -  History of tumor of the central nervous system.&#xD;
&#xD;
          -  Participant requires concomitant treatment with strong CYP3A4 inhibitors or CYP3A4&#xD;
             inducers. If applicable, these drugs must be discontinued 7 days prior to Baseline&#xD;
             (Visit 2).&#xD;
&#xD;
          -  Participant requires concomitant treatment with any prohibited medication, supplement,&#xD;
             or herbal product, including any psychotropic drug or any drug with psychotropic&#xD;
             activity or with a potentially psychotropic component, with the exception of permitted&#xD;
             interventions.&#xD;
&#xD;
          -  Use of an antipsychotic depot within 2 cycles of their respective dosing interval&#xD;
             prior to Screening (Visit 1).&#xD;
&#xD;
          -  Participant requires initiation or termination of psychotherapy within the 3 months&#xD;
             preceding Screening (Visit 1), or plans to initiate, terminate, or change any&#xD;
             outpatient psychotherapy during the course of the study.&#xD;
&#xD;
          -  ECT within 1 month of Screening (Visit 1).&#xD;
&#xD;
          -  Participant is unwilling to discontinue or, in the opinion of the investigator, unable&#xD;
             to safely taper off any protocol-specified prohibited treatment prior to the Baseline&#xD;
             (Visit 2) without significant destabilization or increased suicidality.&#xD;
&#xD;
          -  Participant is currently enrolled in another investigational drug or device study or&#xD;
             participation in such a study within 3 months of Baseline (Visit 2).&#xD;
&#xD;
          -  Known history of human immunodeficiency virus infection.&#xD;
&#xD;
          -  Female participant who entered menarche and is sexually active, and with any of the&#xD;
             following at Screening (Visit 1): positive pregnancy test, nursing, or planning to&#xD;
             become pregnant at any time during participation in the study.&#xD;
&#xD;
          -  Known allergy or sensitivity to the study intervention or its components.&#xD;
&#xD;
          -  History of serious homicidal risk or behavior that resulted in hospitalization or&#xD;
             adjudication (legal sentencing) within 6 months of Screening (Visit 1).&#xD;
&#xD;
          -  History of suicide attempt within 6 months of Screening (Visit 1) in the judgment of&#xD;
             the investigator.&#xD;
&#xD;
          -  The participant has a condition or is in a situation, which, in the investigator's&#xD;
             opinion, may put the participant at significant risk, may confound the study results,&#xD;
             or may interfere significantly with the participant's participation in the study.&#xD;
&#xD;
          -  Current suicidal or homicidal ideation in the judgment of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harmonex Neuroscience Research /ID# 234938</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pillar Clinical Research /ID# 236434</name>
      <address>
        <city>Bentonville</city>
        <state>Arkansas</state>
        <zip>72712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Woodland International Research Group /ID# 236352</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alliance Research /ID# 236261</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prospective Research Innovations Inc /ID# 236098</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <zip>91730</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego Department of Psychiatry /ID# 236466</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pacific Clinical Research Management Group /ID# 234377</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786-3676</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarkis Clinical Trials /ID# 236893</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galiz Research - Palmetto Medical Plaza /ID# 236277</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Florida Research Ph I-IV /ID# 237453</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166-7225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbus Clinical Services, Llc /Id# 234281</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125-5114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Research Center, Inc. /ID# 236515</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research /ID# 234698</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta, LLC /ID# 237391</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlanta Behavioral Research, LLC /ID# 236374</name>
      <address>
        <city>Dunwoody</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AMITA Health St. Mary and St. Elizabeth Medical Ctr /ID# 235857</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60622</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Kennedy Krieger Institute /ID# 236360</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Med Clinical Research Partners LLC /ID# 236071</name>
      <address>
        <city>Irvington</city>
        <state>New Jersey</state>
        <zip>07111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erie County Medical Center /ID# 237204</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Finger Lakes Clinical Research /ID# 236579</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618-1609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati /ID# 236913</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0585</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CincyScience /ID# 236390</name>
      <address>
        <city>West Chester</city>
        <state>Ohio</state>
        <zip>45069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cutting Edge Research Group /ID# 236664</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116-1423</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BioBehavioral Research of Austin /ID# 236479</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759-5290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Clinical Trials /ID# 234444</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401-2928</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>McGovern Medical School /ID# 238506</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Red Oak Psychiatry Associates /ID# 236602</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090-2641</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>AIM Trials /ID# 236368</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Family Psychiatry of The Woodlands /ID# 236426</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Virginia /ID# 236362</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>Bipolar I Disorder</keyword>
  <keyword>Cariprazine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cariprazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

